The clinical trials of Pfizer’s coronavirus vaccine found that the all-cause mortality rate of the vaccinated group was higher than that of the control group, months after the trials were launched, according to a recently released FDA report.
According to the report – which was released by the US Food and Drug Administration to provide background information on its questionable decision to grant full approval for the Pfizer-BioNTech Covid-19 mRNA injection, after initially offering limited emergency use authorisation just six months after the vaccine’s clinical trial began – the total number of deaths reported in the vaccinated group was nearly one-quarter higher than the number of deaths in the placebo group.
Just under 22,000 participants were included in each group, with half receiving the coronavirus vaccine, and half receiving a saline solution injection.
The initial results of the clinical trials suggested a high-level of efficacy for the vaccine in preventing symptomatic cases of COVID-19, an in particular, serious illness from COVID – but lacked significant data on all-cause mortality, due to the short time-frame.
A follow-up assessment of participants completed on March 13th of this year looked at the overall health outcomes of the trial participants, six months after they received either the experimental vaccine or the saline solution injection.
While Pfizer released partial data on the outcomes from the six-month assessment ending March 13th, the new FDA report includes more comprehensive data, and shows a significantly higher number of all-cause fatalities among the vaccinated cohort.
The Pfizer report in late July of this year showed effectively equal all-cause fatality rates between the vaccine and placebo cohorts six months after the tests were conducted, with 15 deaths among the nearly 22,000 vaccine recipients, versus 14 deaths among the nearly 22,000 placebo recipients.